Global Oral Transmucosal Drugs Market - 2023-2030

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,350	195 Pages	DataM Intelligence 4Market Research LLP	May, 2023	DTAM17899749

Best Price Guarantee
Price	from $4,350
Length	195 Pages
Publisher	DataM Intelligence 4Market Research LLP
Published Date	May, 2023
SKU	DTAM17899749

Global Oral Transmucosal Drugs Market - 2023-2030

Market Overview

The global oral transmucosal drugs market reached US$ 15,005.2 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 24,441.4 million by 2030. The oral transmucosal drugs market is expected to exhibit a CAGR of 6.4% during the forecast period (2023-2030).

Globally, chronic or non-communicable diseases are on the rise and are responsible for 73% of all fatalities. Non-communicable illnesses are to blame for 44% of lost disability-adjusted life years and 53% of all fatalities in India. More than a sixth of the world's people reside in India, which has been experiencing significant socio-economic development and an epidemiological trend towards chronic non-communicable diseases led to the rise in the oral transmucosal drugs market growth.

The Coronavirus disease 2019 (COVID-19) pandemic has led to a surge in the need for alternative routes of administration of drugs for end-of-life and palliative care, particularly in community settings. Transmucosal routes include intranasal, buccal, sublingual and rectal. They are non-invasive routes for systemic drug delivery with the possibility of self-administration, or administration by family caregivers. The factors such as growing cases of autoimmune disorders, technological advancements, and oral drugs market developments are boosting the global oral transmucosal drugs market growth.

Market Dynamics

Increase in the incidence of autoimmune disorders and cancer to boost the market growth

For instance, each year, the American Cancer Society estimates the number of new cancer cases and deaths in the U.S., and compiles the most recent data on population-based cancer occurrence and outcomes. In 2022, 1,918,030 new cancer cases and 609,360 cancer deaths were projected to occur in the U.S., including approximately 350 deaths per day from lung cancer, the leading cause of cancer. Thus, the prevelance of cancer boost the market growth.

Technical challenges of transmucosal drug

Transmucosal drug delivery is preferable to oral and parenteral forms of administration since it is non-invasive and enables self-administration or administration by trained carers. Understanding the mechanism of mucosal drug absorption is crucial in order to find medications that are right for transmucosal administration. The intranasal, oral, and rectal mucosa each have particular morphological and physiological traits, but they also have several things in common.

COVID-19 Impact Analysis

Due to supply chain disruption, a government-imposed lockdown, manpower shortages, and limitations on manufacturing activities, the COVID-19 pandemic had a short-term detrimental effect on the market for oral transmucosal medications. Oral transmucosal medication producers, on the other hand, are profiting from coronavirus outbreaks by providing reduced first-pass metabolism with a quick onset of action. These qualities make oral transmucosal medications useful for palliative care and end-of-life care to provide quick symptom alleviation. Since some patients' health has a tendency to rapidly decline in some circumstances, it was essential during the COVID-19 pandemic.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine is estimated to have a minimal impact on the global oral transmucosal drugs market, owing to the low prevalence and absence of key market players in this region. However, the impact of the import and export of raw materials is anticipated to have little influence over the global oral transmucosal drugs market over the forecast period.

Artificial Intelligence Impact Analysis

Artificial intelligence (AI) has become more prevalent in a number of societal fields, most notably the pharmaceutical industry. Artificial neural networks (ANNs), information technology, and wireless communication all play a role in the development of smart medication delivery systems that have the potential to overcome the drawbacks of traditional therapeutic approaches. Devices for regulated drug distribution are more versatile, thanks to wireless connections.

For more details on this report - Request for Sample

Segment Analysis

The global oral transmucosal drugs market is segmented based on product type, indication, route of administartion, distribution channel, and region.

The opioid dependence segment is estimated to hold a majority of the oral transmucosal drugs market share during the forecast period.

The opioid dependence indication holds about 39.6% of the total oral transmucosal drugs market. The growing cases of opioid overdose is driving the segment growth. For instance, according to the World Health Organization 2021, globally about 0.5 million deaths are caused because of drug abuse. Over 70% of these deaths are associated with opioids, accounting for over 30% of those drug overdose deaths.

Moreover, prescribing of opioids in the Canada and U.S. has caused high rates of unacceptable death rates, prescription opioid abuse, and an immense obligation to the affected communities.

Geographical Analysis

Europe is estimated to hold the second-largest share of the global oral transmucosal drugs market during the forecast period.

The Europe region holds the second largest share of the global oral transmucosal drugs market accounting for approximately 29%. The market in the Europe region is being driven by the rising demand for pain management and active regional market participants.

For instance, Aquestive Therapeutics, Inc., a pharmaceutical company that develops drugs to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced in September 2022 that it entered a license and supply agreement for Libervant (diazepam) Buccal Film with Pharmanovia. This agreement will allow Pharmanovia to market Libervant (diazepam) Buccal Film in the European Union, the UK, and other countries.

Competitive Landscape

The major global players in the market include Pfizer Inc., ZIM Laboratories Limited, Aquestive Therapeutics, Inc, IntelGenx Corp, Indivior PLC, C.L.Pharm Co., Ltd, Seoul Pharmaceuticals, Shilpa Therapeutics, Sunovion Pharmaceuticals, Inc, and CURE Pharmaceutical, among others.

Why Purchase the Report?
• To visualize the global oral transmucosal drugs market segmentation based on product, application, and region,as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of oral transmucosal drugs market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global oral transmucosal drugs market report would provide approximately 53 tables, 54figures, and 195 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

1. Methodology and Scope: 1.1. Research Methodology; 1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary: 3.1. Snippet by Product Type; 3.2. Snippet by Indication; 3.3. Snippet by Route of Administration; 3.4. Snippet by Distribution Channel; 3.5. Snippet by Region
4. Dynamics: 4.1. Impacting Factors; 4.1.1. Drivers; 4.1.1.1. Increase in incidence of autoimmune disorders, respiratory problems, and cancer to boost the market growth; 4.1.1.2. The increase in medication and pharmacological therapy usage; 4.1.2. Restraints; 4.1.2.1. Regulatory challenges for transmucosal drug; 4.1.3. Opportunity; 4.1.3.1. Increasing number of research and developments activities; 4.1.4. Impact Analysis
5. Industry Analysis: 5.1. Porter's Five Forces Analysis; 5.2. Supply Chain Analysis; 5.3. Unmet Needs; 5.4. Regulatory Analysis
6. COVID-19 Analysis: 6.1. Analysis of COVID-19; 6.1.1. Before COVID-19 Scenario; 6.1.2. Present COVID-19 Scenario; 6.1.3. Post COVID-19 or Future Scenario; 6.2. Pricing Dynamics Amid COVID-19; 6.3. Demand-Supply Spectrum; 6.4. Government Initiatives Related to the Market During the Pandemic; 6.5. Manufacturers’ Strategic Initiatives; 6.6. Conclusion
7. Russia-Ukraine War Analysis
8. Global Recession Analysis
9. Artificial Intelligence Impact Analysis
10. By Product Type: 10.1. Introduction; 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type; 10.1.2. Market Attractiveness Index, By Product Type; 10.2. Tablets; 10.2.1. Introduction; 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%); 10.3. Films; 10.4. Liquids & Spray; 10.5. Others
11. By Indication: 11.1. Introduction; 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication; 11.1.2. Market Attractiveness Index, By Indication; 11.2. Opioid Dependence *; 11.2.1. Introduction; 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%); 11.3. Neurological Disorders; 11.4. Erectile Dysfunction; 11.5. Nausea and Vomiting; 11.6. Others
12. By Route of Administration: 12.1. Introduction; 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration; 12.1.2. Market Attractiveness Index, By Route of Administration; 12.2. Sublingual Mucosa *; 12.2.1. Introduction; 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%); 12.3. Buccal Mucosa; 12.4. Others
13. By Distribution Channel: 13.1. Introduction; 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel; 13.1.2. Market Attractiveness Index, By Distribution Channel; 13.2. Retail Pharmacies*; 13.2.1. Introduction; 13.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%); 13.3. Hospital Pharmacies; 13.4. Online Pharmacies
14. By Region: 14.1. Introduction; 14.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region; 14.1.2. Market Attractiveness Index, By Region; 14.2. North America; 14.2.1. Introduction; 14.2.2. Key Region-Specific Dynamics; 14.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type; 14.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication; 14.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration; 14.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel; 14.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country; 14.2.7.1. The U.S.; 14.2.7.2. Canada; 14.2.7.3. Mexico; 14.3. Europe; 14.3.1. Introduction; 14.3.2. Key Region-Specific Dynamics; 14.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type; 14.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication; 14.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration; 14.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel; 14.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country; 14.3.7.1. Germany; 14.3.7.2. The U.K.; 14.3.7.3. France; 14.3.7.4. Italy; 14.3.7.5. Spain; 14.3.7.6. Rest of Europe; 14.4. South America; 14.4.1. Introduction; 14.4.2. Key Region-Specific Dynamics; 14.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type; 14.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication; 14.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration; 14.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel; 14.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country; 14.4.7.1. Brazil; 14.4.7.2. Argentina; 14.4.7.3. Rest of South America; 14.5. Asia-Pacific; 14.5.1. Introduction; 14.5.2. Key Region-Specific Dynamics; 14.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type; 14.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication; 14.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration; 14.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel; 14.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country; 14.5.7.1. China; 14.5.7.2. India; 14.5.7.3. Japan; 14.5.7.4. Australia; 14.5.7.5. Rest of Asia-Pacific; 14.6. Middle East and Africa; 14.6.1. Introduction; 14.6.2. Key Region-Specific Dynamics; 14.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type; 14.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication; 14.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration; 14.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
15. Competitive Landscape: 15.1. Competitive Scenario; 15.2. Market Share Analysis; 15.3. Mergers and Acquisitions Analysis
16. Company Profiles: 16.1. Pfizer Inc.*; 16.1.1. Company Overview; 16.1.2. Product Portfolio and Description; 16.1.3. Financial Overview; 16.1.4. Key Developments; 16.2. ZIM Laboratories Limited; 16.3. Aquestive Therapeutics, Inc; 16.4. IntelGenx Corp; 16.5. Indivior PLC; 16.6. C.L.Pharm Co., Ltd; 16.7. Seoul Pharmaceuticals; 16.8. Shilpa Therapeutics; 16.9. Sunovion Pharmaceuticals, Inc; 16.10. CURE Pharmaceutical.; LIST NOT EXHAUSTIVE
17. Appendix: 17.1. About Us and Services; 17.2. Contact Us